A Phase II Study of Lenalidomide and Low-Dose Dexamethasone in Combination with Dalteparin in Previously Untreated Multiple Myeloma.
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Lenalidomide (Primary) ; Dalteparin sodium; Dexamethasone
- Indications Embolism and thrombosis; Multiple myeloma
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 02 Mar 2017 Planned End Date changed from 1 Jan 2017 to 31 Dec 2017.
- 02 Mar 2017 Status changed from active, no longer recruiting to discontinued.